MedTrace Logo

Alveolar Ridge Splitting With Simvastatin/PRF Composite and Simultaneous Implant Placement

NCT07692620 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-07-09

No results posted yet for this study

Summary

This randomized controlled clinical trial evaluated the effectiveness of platelet-rich fibrin (PRF) and a simvastatin/PRF composite combined with a xenogeneic bone graft during alveolar ridge splitting with simultaneous implant placement in patients with horizontal alveolar ridge deficiency. Twenty-one participants were randomly allocated into three groups: a control group receiving xenogeneic bone graft alone, a PRF group receiving xenogeneic bone graft blended with PRF, and a simvastatin/PRF group receiving xenogeneic bone graft blended with a simvastatin/PRF composite. Clinical and radiographic outcomes were assessed to compare horizontal and vertical bone gain, bone density, and keratinized tissue width after treatment.

Conditions

  • Alveolar Ridge Atrophy
  • Tooth Loss

Interventions

PROCEDURE

Alveolar Ridge Splitting with Simultaneous Implant Placement

Surgical expansion of the horizontally deficient alveolar ridge followed by immediate dental implant placement.

BIOLOGICAL

Xenogeneic Bone Graft

Xenogeneic bone graft used to augment the expanded alveolar ridge around the implant.

BIOLOGICAL

Platelet-Rich Fibrin (PRF)

Autologous platelet-rich fibrin prepared from the participant's blood and blended with the xenogeneic bone graft.

DRUG

Simvastatin

Locally applied simvastatin incorporated into the PRF/xenogeneic bone graft composite to enhance bone regeneration.

Sponsors & Collaborators

  • Maruwan Ali Alteer

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-02
Primary Completion
2026-05-02
Completion
2026-05-30

Countries

  • Egypt

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07692620 on ClinicalTrials.gov